Media
[News] Hua Medicine Will Present Research Results and Be Invited to Broadcast Series of TV Reports at the 2025 American Diabetes Association (ADA) Scientific Sessions
June 18, 2025，Shanghai, China
Hua Medicine ("the Company", stock code: 2552.HK) announced today that it will present the research results of dorzagliatin, the Company's global first-in-class glucokinase activator (GKA), at the 85th American Diabetes Association (ADA) Scientific Sessions. The Company has also been invited to broadcast a series of TV reports at the annual meeting venue.
Hua Medicine will present the latest basic research results through poster presentation. The animal research shows that the combination of dorzagliatin with the DPP-4 inhibitor sitagliptin can improve blood glucose levels, increase insulin secretion, and enhance GLP-1 secretion. The combination therapy was more effective than dorzagliatin alone. The blood chemistry analysis indicates that the combination therapy has potential benefits for liver function improvement and lipid lowering (especially LDL).
Another investigator-initiated real-world study has clinically observed and demonstrated that dorzagliatin can significantly improve blood glucose levels in type 2 diabetes patients and restore their glycemic homeostasis and β-cell function.
In addition, Hua Medicine has been invited again to broadcast a series of films on ADA TV, the official television channel, during the ADA Scientific Sessions. The films will elaborate on the global diabetes management landscape and the clinical application value of dorzagliatin in different fields. The series will be played across ADA sessions and the media zone during the annual meeting.
The ADA Annual Scientific Sessions is the largest and most important diabetes conference in the world. Every year, tens of thousands of researchers and practitioners from all over the world attend this event to report and exchange significant progress in diabetes research and treatment. Since 2014, Hua Medicine and its clinical experts have consistently presented innovative and groundbreaking results of basic and clinical research in the field of metabolic disease at the ADA Annual Scientific Sessions.
This year's ADA Annual Scientific Sessions will be held in Chicago, USA from June 20 to 23, 2025.
Hua Medicine Shcedule
Poster code: 893-P | |
Title： | Long Term Administration of Dorzagliatin Combined with Sitagliptin for the Management of Glucose Homeostasis in High Fat Diet Induced Obesity Mice |
On-site display time: | June 22, 12:30 p.m. - 13:30 p.m. (Central Standard Time) |
Sessions: | 12-D Clinical Therapeutics—Other Therapeutic Agents |
Location： | Poster Hall, Hall F1 |
Poster code：2004-LB | |
Title: | Interim Analysis of a Real-World Study——Glucokinase Activator Dorzagliatin Demonstrates lmproved Glycemic Homeostasis and β-Cell Function in T2DM |
On-site display time: | June 22, 12:30 p.m. - 13:30 p.m. (Central Standard Time) |
Sessions： | Late Breaking Poster |
Location： | Poster Hall, Hall F1 |
About Hua Medicine
Hua Medicine (The "Company") is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (华堂宁®) (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing (华堂宁®) was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.
For more information
Hua Medicine
Website: www.huamedicine.com
Investors
Website: ir@huamedicine.com
Investors
Website: pr@huamedicine.com
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
